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Graft-versus-host disease (GvHD) was recognised as early as the 
1960s by Gowans[1] as an immunological attack by the lymphoid cells 
of a graft against tissues of the host. It was subsequently described by 
Billingham[2] in 1966 in his historic Harvey Lecture, who described 
the conditions for its development that stand to date: (i) the 
graft should contain immunologically competent cells; (ii) the host 
antigens produced should not be present in the transplant donor; 
and (iii) the recipient should be incapable of generating an efficient 
response to destroy the transplanted cells. 
GvHD became well known to the scientific community as a major 
complication of haematopoietic stem-cell transplantation (HSCT); 
donor T-cells react to host antigens on antigen-presenting cells 
(APCs,) causing further activation of donor cytotoxic T-cells, natural 
killer cells (NKCs) and macrophages, which target tissue-specific 
cells in the host, ending in organ damage. It is a multiorgan disease 
that can also complicate solid-organ transplantation and in rare cases, 
liver transplantation.
The clinical presentation of GvHD has been extensively described 
after allogeneic bone-marrow transplantation; however, it can also 
complicate solid-organ transplantation in adults and in children.[3-7] 
GvHD after solid-organ transplant may be under-reported and 
under-investigated owing to the difficulty in its recognition. Early 
symptoms are nonspecific and resemble common viral infections or 
drug reactions, and may therefore be easily attributed to other causes. 
Currently, there are no universal treatment guidelines for 
GvHD after paediatric liver transplantation; steroids and other 
immunosuppression agents have been tried, but are only described 
in individual case reports and case series. The purpose of this review 
was to review all reported cases of GvHD reported in paediatric liver 
transplantation to date.
Methods
We searched PubMed for English-language full-text articles published 
between 1990 and 2017 for eligible studies. The following search 
terms were used both alone and in combination: ‘GvHD’, ‘aGvHD’ 
[acute graft-versus-host disease], ‘graft-versus-host-disease’, ‘cGvHD’ 
[chronic graft-versus-host disease], ‘paediatric’, ‘pediatric’, ‘liver’, 
‘transplantation’, ‘solid organ’, ‘graft’, ‘multivisceral’, ‘kidney’, ‘pancreas’, 
‘spleen’, ‘prevention’, ‘treatment’, ‘steroids’, ‘refractory’, ‘cyclosporine’, 
‘FK’, ‘tacrolimus’, ‘sirolimus’, ‘MMF’ [mycophenolate mofetil], 
‘ATG’, ‘anti-thymocyte globulin’, ‘alemtuzumab’, ‘rituximab’, ‘MSCs’ 
[mesenchymal stem cells], ‘infliximab’, ‘etanercept’, ‘basiliximab’, 
‘ECP’ [extracorporeal photopheresis]. The references of the articles 
were also searched for relevant publications. 
The search found 1 case series of paediatric GvHD after isolated 
liver transplantation, 2 case series containing paediatric cases of 
GvHD after liver transplantation in mixed adult and paediatric 
populations, and 5 case reports of paediatric GvHD after liver 
transplantation that were individually published.[8-17] Studies that 
described GvHD after combined liver/intestinal, pancreatic, spleen, 
multivisceral transplantation or combinations of the above, are 
described briefly. 
Pathophysiology
The immunobiology and pathogenesis of acute GvHD can be 
summarised in three steps. 
Step 1: (occurs pre-GvHD, beginning before the donor cells 
are implanted). Prior disease, comorbidities, infection and the 
conditioning regimen damage the host tissues, resulting in activation 
of the host immune cells and the secretion of pro-inflammatory 
cytokines: tumour necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), 
IL-6 and interferon gamma (IFN-γ).[18] These cytokines upregulate 
cell surface adhesion molecules and major histocompatibility 
complex antigens on host APCs, which trigger a response by mature 
donor T-cells.[19] At the same time, the donor tissue is exposed to a 
foreign environment.[20] 
Step 2: Donor CD4+ and CD8+ T-cells are activated by host and 
donor antigen-presenting cells (APCs) and by pro-inflammatory 
cytokines, resulting in a Th1 response. This response activates further 
T-cells and natural killer cells (NKCs), and induces macrophages to 
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release TNF-a and IL-1. The most potent APCs are the dendritic 
cells (DCs), which are activated by inflammatory cytokines, 
lipopolysaccharides (LPS) and necrotic cells damaged by the host 
conditioning.[18] Naive T-cells proliferate and differentiate following 
activation. IFN-γ is released from activated T-cells and upregulates 
adhesion molecules and chemokines, which in turn mediate damage 
to the skin and gastrointestinal (GI) tract through nitric oxide (NO) 
induction and Fas.[21] 
Step 3: Damage to the target tissues is specific and is caused 
primarily by activated T-cells’ cytotoxic damage against host 
cells through Fas-Fas ligand-mediated apoptosis in the liver, and 
perforin-granzyme-B-mediated cytolysis in the GI tract and the 
skin.[19] The mechanism of action depends also on positive feedback 
of inflammatory molecules adding to the pre-existing cytokine 
cascade, thus increasing the T-cell activity.[6] 
Clinical manifestations of GvHD
GvHD after paediatric solid-organ transplantation occurs 
infrequently, and GvHD after paediatric liver transplantation has 
been rarely reported. It has been described more commonly in adult 
patients in the literature, with a varying incidence of 0.1 - 2%, and is 
related to high mortality and morbidity for those adults affected.[3,5,22] 
The most common manifestations of GvHD have been described 
after HSCT, and involve the skin, the GI tract, the liver and rarely the 
eyes and the oral mucosa.[19,20,23] 
The most common manifestations after liver transplantation are 
fever and a skin rash. They usually occur within 1 - 8 weeks after the 
transplantation. The rash is maculopapular and it can progress to 
erythroderma or bullous desquamation in more severe stages. GvHD 
can also become a multisystem disease with involvement of the GI 
tract and the bone marrow. GI symptoms include diarrhoea, emesis, 
blood in the stools or anorexia and abdominal pain. The symptoms 
are attributed to the lymphocyte infiltration and subsequent loss 
of absorption of the intestinal mucosa. The bone marrow, when 
affected, usually manifests with thrombocytopenia, neutropenia, 
lymphopenia, and haemolytic anaemia (HA). 
The main difference in GvHD after liver transplantation to 
that after HSCT lies within the function of the transplanted liver; 
in GvHD after liver transplantation, this remains normal. The 
immunocompetent donor B-lymphocytes (‘passenger lymphocytes’) 
are transferred in or with the liver (in the lymphatics or lymph nodes 
that accompany the donor liver), and they are activated on host 
APCs; as the lymphocytes and liver are both of donor origin, the liver 
function remains intact. 
Another type of GvHD has been described after solid-organ 
transplantation that demonstrates features of a humoral rather 
than a cellular response; evidence of haemolysis and fever have 
been demonstrated in ABO-unmatched transplants, with circulating 
red-cell bound isohaemagglutinins found in the peripheral blood 
of such patients, against their A or B antigens.[24] These antibodies 
are thought to originate from B-passenger lymphocytes, and this 
response leads to haemolysis. 
GvHD after paediatric small-
bowel, combined liver/intestinal, 
multivisceral and other solid-organ 
transplantation
GvHD has been described in paediatric liver/intestinal transplan-
tation (LITx), small-bowel transplantation (SBTx), multivisceral 
transplantation (MVTx), modified multivisceral transplan- 
tation (MMVTx) and other solid-organ transplantation, such as 
pancreatic. 
Intestinal transplantation
Mazariegos et al.[25] reported the incidence of GvHD in intestinal 
transplantation to be around 6.5%. They presented 8/122 paediatric 
patients (3 after SBTx and 5 after MVTx) with GvHD, diagnosed with 
histology and blood chimerism studies. Andres et al.[26] also reported 
10% of intestinal transplantation patients (post-SBTx, LITx and 
MVTx) who subsequently developed GvHD. 
 Multivisceral transplantation
The Spanish group of Feito-Rodrıguez et al.[27] reported that GvHD 
occurred in higher rates in MVTx and MMVTx compared with 
solid-organ transplant (e.g. liver grafts), and also compared with SBTx 
or combined liver/SBTx. This may be due to the higher amount of 
lymphoid tissue in the multivisceral grafts. In SBTx and MVTx, the 
incidence varies from 9 - 29.4%, and the clinical symptoms are similar 
to those of GvHD after HSCT, involving the skin, GI tract, liver and 
bone marrow.[28] 
Severity of GvHD
GvHD can be categorised as either acute graft-versus-host disease 
(aGvHD) or chronic graft-versus-host disease (cGvHD), depending 
on the presentation of symptoms in relation to the transplantation. 
Acute GvHD occurs when symptoms evolve in the first 100 days of 
transplant, and cGvHD after the 100th day of the surgery. There is also 
another classification, according to the American Society for Blood 
and Marrow Transplantation[29,30] issued in 2006, of late-onset aGvHD 
(symptoms occurring after day 100), and an overlapping entity of 
aGvHD and cGvHD occurring any time after transplant.
To quantify the severity of aGvHD after HSCT, the modified Seattle-
Glucksberg score is commonly used. The four grades of aGvHD are 
based on the extent of the involvement of the skin, the GI tract and the 
liver (Table 1). For cGvHD, another classification is utilised (Table 2). 
To date, there is no known grade system/index to accurately evaluate 
the severity of GvHD after liver transplantation as a multiorgan 
entity involving the skin, the gut, and possibly the bone marrow. In 
contrast to the scales described in Tables 1 and 2, in GvHD post-liver 
transplant the liver is spared; therefore, to quantify its severity with the 
Glucksberg grade would be a misconception. 
Presentation
The case reports and case series are summarised in Table 3. The 
data add up to a total of 13 patients who developed GvHD after liver 
transplantation (left lateral segment orthotopic liver transplantation 
(LLS OLT) or living-donor liver transplantation (LDLT)) in the 
literature. 
Time of presentation
In the presented studies, the earliest presentation of aGvHD after liver 
transplantation was on day 11 in the case report of Cattral et al.,[8] and 
the latest presentation of aGvHD was on day 95 in a case report by 
Comenzo et al.,[10] although no skin biopsy was obtained in the latter 
case, and the diagnosis of aGvHD was based only on clinical findings 
and response to treatment. 
In one case report by Dunn et al.,[12] a patient presented with features 
of aGVHD and cGvHD, confirmed by chimerism and a positive skin 
biopsy, 6 years after liver transplantation. Three more patients in other 
case series and case reports presented with late-onset aGvHD at 140, 
160 and 480 days after transplantation.[9,15,16]
Presenting symptoms
The most common symptom identified was skin manifestations, 
affecting 11 out of the 13 patients (84.6%). The rash was predominantly 
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described as maculopapular, which in 4/11 (36.4%) cases affected more 
than 75% of the patient’s body surface and involved desquamation; in 
2 cases, it was described as a vesiculopapular rash or a generalised 
erythema, respectively. 
Gastrointestinal symptoms were described in 9/13 (69.2%) cases, 
with diarrhoea being the principal symptom in 8 cases. Vomiting and 
blood in the stools accounted for 3/9 (33.3%) and 2/9 (22.2%) of the 
cases, respectively.
Fever (not associated with intercurrent infections) was reported in 
8/13 (61.5%) patients, although the incidence may have been higher 
as this information was not available for 3 patients. 
Haematological or BM involvement was reported in 10/13 
(76.9%) of patients. Eight patients (61.5%) developed pancytopenia, 
1/8 presenting with HA and subsequently pancytopenia, while 
another developed HA and lymphopenia. In 1 patient anaemia was 
mentioned, but no other information was provided. 
Of the 3 patients who developed HA, Cattral et al.[8] described 
HA preceding the GvHD symptoms (as possible humoral GvHD), 
whereas Pinna et al.[9] reported a transient HA that was self-limiting 
and associated with the formation of isoagglutinins formed by the 
donor against the host red blood cells.
Diagnosis 
Several techniques and tests have been used to identify GvHD in the 
skin, the GI or the BM, with skin biopsy predominantly used for the 
skin manifestations; endoscopy and GI histology for the intestinal 
symptoms; and in recent years, fluorescence in situ hybridisation 
(FISH) and immunostaining for donor HLA markers in peripheral 
blood.[26,31,32] 
GvHD symptoms are usually nonspecific, and might be missed 
or misinterpreted as a drug reaction or an infection; therefore, 
biopsies of all involved tissues tend to be supportive in establishing 
the diagnosis, but their sensitivity and specificity are low.[19,33-35] 
Skin biopsy may reveal apoptotic bodies, lymphocytic infiltration 
of the epithelium, lymphocytes out of the vessels (exocytosis) 
and vacuolisation of the basal epithelial layer in the native 
involved organs – all suggestive but not pathognomonic of GvHD 
(Fig. 1).[26,27,34-36] 
Histopathological grades of aGvHD have been suggested for 
GvHD after HSCT since 1974. A four-point grading system was 
introduced by Lerner et al.,[37] where grade I changes consisted of 
basal-cell vacuolation, grade II of cell necrosis, grade III dyskeratosis 
and spongiosis, and grade IV epidermal sloughing.Research showed 
that it is almost impossible to distinguish drug-induced dermatitis 
from aGvHD, as the lesions described in histopathology are almost 
identical.[38] Furthermore, there was no correlation between the 
histopathological findings and the degree of severity of aGvHD 
(Fig. 2).[39,40]
Donor chimerism studies or immuno-staining for donor HLA 
markers are methods used to detect the donor immunocompetent 
cells in the recipient’s peripheral blood. In cases of sex-mismatched 
donor/recipient, the donor cells can be identified by FISH for X and Y 
chromosomes; however, the FISH analysis is quantitative and it does 
not distinguish between T or B lymphocytes.[31,32]
From the total of 13 patients with GvHD presented in Table 1, 5 
had a positive skin biopsy (38.5%), and another 30.8% had a positive 
GI biopsy, with 7 patients presenting with symptoms of both GI and 
skin GvHD, but biopsy confirmation in only one organ. Eight (61.5%) 
patients had positive donor HLA markers   in peripheral blood 
and one (7.7%) had a positive bone marrow aspirate. There were 2 
patients in the same case series by Kamei et al.[13] for which there are 
no data on the diagnostic tests used to establish the diagnosis. 
Risk factors
The literature on risk factors for GvHD post liver transplantation 
is limited. Most studies aiming to identify potential risk factors for 
GvHD have been reported after MVTx or combined LITx in the 
literature, but not in liver grafts alone. Wu et al.[41] reported a series 
of 241 patients (both children and adults), in which the younger 
children, especially those younger than 5 years old, presented with 
a higher incidence of GvHD; furthermore, recipients of MVTx 
(with or without a liver graft) also had a higher incidence of GvHD 
compared with isolated SBTx recipients, and the inclusion of spleen 
in the MVTx grafts, or recipient splenectomy, was also associated 
with GvHD.
Past studies have shown that an HLA-homogenous graft with 
one-way donor-recipient HLA matching may lead to a higher 
incidence of GvHD, putting living-related liver transplantations 
Fig. 1. Skin biopsy. Progression of histologic changes from acute to chronic 
cutaneous GvHD. (A) Screening skin biopsy, day 85. A focal apoptotic body 
formation is present at the tips of rete ridges (arrow) with focal surrounding 
lymphocytic satellitosis (original magnification ×400). (B) Lichen planus-like 
chronic GvHD, day 426. The thickened epidermis displays orthokeratosis, 
hypergranulosis, and acanthosis. The striking lichenoid reaction along 
the damaged basal layer includes a prominent lymphocytic inflammation 
and infiltration, apoptotic changes, loss of rete ridges, and prominence of 
the superficial vascularity (original magnification ×100). (C) Progression 
of GVHD from panel A into a sclerotic stage, day 382. A zone of dense, 
relatively avascular homogenized collagen has replaced the papillary and 
upper reticular dermis (original magnification ×63). (D) High-power view 
shows a hyperkeratotic epidermis with flattening of the rete ridges, vacuolar 
changes, and lymphocytic infiltration along the basal layer, with disruption 
of the epidermal melanin unit and with coarse clumps of melanin in the 
epidermis and incontinent melanin pigment in the sclerotic papillary dermis 
(original magnification ×160). Reproduced from Shulman et al.[36] with 
permission from Elsevier Inc. under the terms of the Creative Commons 
Attribution-NonCommercial-No Derivatives License (CC BY NC ND).
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from a parental donor at higher risk of this 
complication. The mechanism of action lies in 
the fact that T-cells from donors homozygous 
to all HLA loci in the recipient present no 
HLA antigens that can be recognised as foreign 
and therefore they cannot lead to rejection. 
However, the donor’s passenger circulating 
immune cells can identify the recipients’ HLA 
as foreign, as half of them derive from the 
other parent. This could also lead to chimerism 
and GvHD. Whitington et al.,[11] reported one 
such case that led to cGvHD.[11] The group of 
Kamei et al.[13] (Table 1) analysed 8 cases of 
fatal GvHD  and also 906 living-donor liver 
transplantations, and suggested that the risk 
for fatal GvHD could depend on the number 
of loci with donor-dominant one-way HLA 
matching; if the donor is homogenous with 
one-way HLA matching at three loci, the risk 
is significantly higher. 
Another risk factor mentioned in the 
literature is the underlying diagnosis, 
especially a pre-existing immunodeficiency. 
Smith et al.[42] described one paediatric 
patient with a pre-existing undiagnosed 
unclassified combined immunodeficiency, 
which led to bone-marrow aplasia, higher 
susceptibility to infections and, finally, 
multiorgan failure and death.
Pinna et al.[9] (Table 1) analysed a series 
of 124 paediatric liver transplantations, 
and of those, only 3 developed GvHD 
(2.4%). However, cytomegalovirus infection 
is suggested to have played a role, as the 
infection itself, in combination with the use 
of immunocompromising drugs, may have 
led to an increased ‘cytokine storm’ response 
of donor T-cells to host antigens, thereby 
increasing the risk of GvHD.
Treatment 
The most common treatment of GvHD 
after liver transplantation is steroids. 
Methylprednisolone (MEP) or prednisolone 
(PSL) have been used widely in treating 
GvHD after HSCT, after MVTx, and after 
isolated liver transplantation. Steroids 
successfully disrupt the three steps of the 
pathophysiology of GvHD. The success 
rate of steroids in treating GvHD was 
found to be higher in patients after a liver 
transplantation (83%) compared with those 
who also received an intestinal graft (46%).[6]
A second approach is the discontinuation 
of the immunosuppression to treat GvHD; 
in 4/13 (30.8%) patients described above, 
trials of weaning or completely stopping 
immunosuppression were reported. Out of 
the 4 cases, 2 continued to have uncontrolled 
GvHD, whereas in the other 2, the GvHD 
resolved. 
Fig. 2. Cutaneous grade 2 GvHD. Note vacuolar change of basal cell layer and dyskeratotic cells in 
epidermis in all biopsies. The amount of infiltrate varies markedly. All of these biopsies were taken 
between day 2l and day 25 post transplantation, and all patients had clinical GvHD and comparable 
peripheral white blood cell counts. (A) Prominent mononuclear-cell infiltrate in the upper part of 
the dermis. (Haematoxylin-eosin stain, original magnification ×250.) (B) Prominent exocytosis of 
mononuclear ceils into the epidermis. (Haematoxylin-eosin stain, original magnification ×260.) 
(C) Prominent mononuclearcell infiltrate in dermis and prominent exocytosis into epidermis. 
(Haematoxylin-eosin stain, original magnification ×250.) (D) Minimal infiltrate in both epidermis and 
dermis. (Haematoxylin-eosin stain, original magnification ×250.) (E) Focal distribution of infiltrate 
is evident on left side of photomicrograph. (Haematoxylin-eosin stain, original magnification ×160.). 
Reproduced from Hymes et al.[39] with permission from Elsevier Inc.
Table 2. Chronic graft-versus-host disease classification
Grade Criteria 
Mild 1 or 2 organs mildly affected AND no pulmonary involvement 
Moderate 3 organs mildly affected OR 1 organ moderately affected OR mild pulmonary involvement 
Severe 1 organ severely affected OR moderate or severe pulmonary involvement 
Table 1. Acute graft-versus-host disease grading: Modified Glucksberg grade
Skin (affected surface) Liver (bilirubin mg/dL) GI tract (fluid loss;  mL/kg/day)
Stage
1 <25% 2.0 - 3.0 >30 mL/kg
2 25 - 50% 3.1 - 6.0 >60 mL/kg
3 >50% or erythroderma 6.1 - 15.0 >90 mL/kg
4 Bullae desquamation >15 >90 mL/kg or severe abdominal pain +/- ileus
Glucksberg grade Skin stage Liver stage GI stage
I 1 - 2 0 0
II 3 1 1
III - 2 - 3 2 - 4
IV 4 4 -
GI = gastrointestinal.
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Pinna et al.[9] reported 1 case of weaning immunosuppression that was 
followed by the development of acute cellular rejection of the graft, 
so that immunocompromising drugs had to be restarted. The patient 
had a second episode of GvHD, and was treated with cyclosporine A, 
steroids and MMF, and his GvHD subsequently resolved. 
Dunn et al.[12] used high doses of intravenous steroids for GvHD 
of the skin and GI tract, with no response. On the second trial of 
weaning immunosuppression, the GvHD resolved, although acute 
rejection of the graft occurred and it was managed by adding 
tacrolimus to the treatment regimen. 
Other examples of withdrawing immunosuppression ended in 
resolution of the GvHD without rejection of the graft, but in these 
case reports the patients were adults.[43] 
In conclusion, GvHD has been treated first-line either by 
augmentation of immunosuppression (i.e intravenous MEP) or by 
reduction of immunosuppression (i.e. stopping ciclosporin in cases), 
with variable and unpredictable results. 
Novel therapies
For recipients who developed aGvHD and did not respond to first-
line treatment with steroids, several immunosuppressive agents 
have been proposed, but studies derive mainly from the experience 
of GvHD cases after HSCT, especially those with cutaneous 
manifestations. There is currently no consensus on a single therapy 
of immunosuppression for these cases.[44] Novel therapies include 
MSC therapy and ECP.
Bone-marrow-derived CD34 fibroblast-like MSCs are known 
to differentiate into numerous types of tissues (muscle, bone, fat, 
etc.) and have the property of migrating to damaged tissues; they 
can produce chemokines and nitric oxide (NO). NO plays a role 
in macrophage function, cytokine receptor expression and T-cell 
receptor signalling, and regulating T-cell immunity pathways. MSCs 
are thought to respond to pro-inflammatory cytokines such as 
IFN-γ, IL-1α, IL-1β and TNF-α, and in turn (i) upregulate the 
inducible NO synthase gene, leading to NO production, and 
(ii) produce leukocyte chemokines which bring immune cells 
(T-cells, B-cells and APCs) close to the NO production and lead to 
immune-cell suppression. By these mechanisms of action, MSCs 
constitute a new immunosuppressive and immunomodulatory drug 
that ameliorated GvHD symptoms in mouse experiments.[45] Two 
paediatric patients have been described where MSCs were given 
with good results.[6] 
ECP is now being used as a novel secondary therapy for 
GvHD. The patient’s blood is leukophoresed and centrifuged to 
remove the leukocyte-enriched buffy coat. This layer of buffy 
coat is photosensitised and irradiated with UVA light, then 
reinfused to the patient. This causes an immunomodulatory effect, 
upregulating anti-inflammatory cytokines and down-regulating 
pro-inflammatory cytokines. It has been described in a child after 
MVTx; however, there are no data regarding its use in patients post 
liver transplantation.[46,47] 
Other monoclonal antibodies have also been used for GvHD, 
especially after HSCT. Infliximab (anti-TNF-α) and etanercept 
have been used, especially in steroid-resistant (SR) gastrointestinal 
GvHD after HSCT, but their use is limited owing to the increased 
incidence of fungal infections.[39] These drugs, as well as anti-
interferon-gamma (anti-IFN-γ) agents, can impede and block the 
action of the cytokine storm, ameliorating the symptoms of GvHD. 
Polyclonal anti-thymocyte globulin (ATG), humanised or 
chimeric monoclonal antibodies have been used for severe visceral 
manifestations of GvHD.[48,49] In the reviewed literature, three case 
studies were found where ATG was used in uncontrolled GvHD: 
in the first, it had a positive short-term effect; in the second it did 
not have any effect; and in the third, it improved the skin but not the 
bone-marrow manifestations, and the recipient died due to sepsis. 
Alemtuzumab is another immunosuppressive drug used in GvHD 
after HSCT, and in some cases, has been used as a second-line 
treatment in GvHD after liver transplantation. It is a humanised 
monoclonal antibody targeting the CD52 antigen expressed on 
T-cells, B-lymphocytes, macrophages and dentritic cells, all of 
which are involved in the pathophysiology of aGvHD. In a study in 
Grenoble in 2014, it was used in 24 adult patients with SR GvHD after 
HSCT. The response rate was 62.4%.[50] 
Imatinib mesylate has also been proposed as a novel treatment for 
cGvHD, but its mechanism of action is as an antifibrotic agent rather 
than an immunosuppressive drug. It inhibits kinases (i.e. platelet-
derived growth factor receptor). It has been used in cases of fibrotic 
cutaneous cGvHD with good response.[51]
Lastly, a new suggested treatment for GvHD after HSCT is 
human serum-derived alpha-1-antitrypsin (A1AT), as it is known 
to downgrade the production of pro-inflammatory cytokines and 
upregulate anti-inflammatory cytokines. It has been found that A1AT 
(i) inhibits proteases (i.e. proteinase-3 (PR-3)), and at the same time 
(ii) facilitates the production of anti-inflammatory agents, such as 
IL-1 receptor antagonists and IL-10. By decreasing the production of 
TNF-α and IL-1β and inhibiting the release of IL-8, it is a promising 
therapy. It has been described in mouse models of HSCT in recent 
years, and has been proposed in other review studies as a potentially 
safe treatment for a broad spectrum of immune-mediated conditions, 
including GvHD.[52,53]
Prevention
Several studies have used different immunosuppression protocols 
(induction and/or maintenance) and studied parameters possibly 
associated with the prevention of GvHD. Andres et al.[26] suggested 
using ATG or basiliximab (chimeric monoclonal antibody against 
IL-2 receptor) on top of tacrolimus and steroids in intestinal 
transplantation, but failed to show a significant difference in 
reduction of GvHD between the group of patients that received the 
ATG/basiliximab and the one that did not. 
Whitington et al.,[11] in their case report, attempted a course of 
ATG for GvHD of the bone marrow that had a positive transient 
effect on the blood counts; however, after bone-marrow recovery the 
patient continued to suffer from chronic GvHD due to chimerism, 
leading to recurrence of donor-derived circulating cells. 
Schäppi et al.,[14] in a case report, suggested giving alemtuzumab 
(for T-cell suppression) in a patient with severe uncontrollable 
GVHD after LDLT; however, it did not help. 
Outcomes
GvHD is a serious multiorgan complication with high morbidity 
and mortality although the symptoms may show partial or complete 
resolution.[42] Amplified immunosuppression with PSL or MEP or 
other drugs was reported in a total of 8/13 patients, 3 of whom 
developed uncontrolled GvHD. In 2 cases, there were no available 
data on the treatment they received after GvHD presentation. For 3 
patients, management suggested withholding immunosuppression. 
In the reviewed literature, 7/13 (53.8%) of the cases were reported 
as having complete resolution of GvHD, whereas 46.2% ended in 
uncontrolled GvHD (multiorgan involvement, cGvHD or death). 
Of the 7 patients whose GvHD resolved, 5 received treatment 
with MEP or PSL, or augmentation of immunosuppression. The 
remaining 2 patients whose GvHD resolved were treated with 
discontinuation of immunosuppression. 
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Conclusion
GvHD after liver transplantation is a rare complication, but has a 
high mortality rate. Prompt consideration of symptoms is desirable 
to initiate treatment early.
A maculopapular skin rash, especially accompanied by fever, 
should always be considered as a sign of GvHD, and should prompt 
early investigation and modification of the treatment. 
Biopsies from all the tissues involved can help to differentiate 
between GvHD staging and monitoring, and although the 
histolopathology may not be specific for GvHD, it may help to 
establish the diagnosis. 
Early diagnosis, early immune-therapy modification and the 
promise of novel therapies may improve the outlook of GvHD after 
liver transplantation in the future. 
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